IBDEI0ZV ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16534,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Amyotrophy
 ;;^UTILITY(U,$J,358.3,16534,1,4,0)
 ;;=4^E11.44
 ;;^UTILITY(U,$J,358.3,16534,2)
 ;;=^5002648
 ;;^UTILITY(U,$J,358.3,16535,0)
 ;;=E11.59^^88^850^7
 ;;^UTILITY(U,$J,358.3,16535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16535,1,3,0)
 ;;=3^Diabetes Type 2 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,16535,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,16535,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,16536,0)
 ;;=E11.638^^88^850^25
 ;;^UTILITY(U,$J,358.3,16536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16536,1,3,0)
 ;;=3^Diabetes Type 2 w/ Oral Complications
 ;;^UTILITY(U,$J,358.3,16536,1,4,0)
 ;;=4^E11.638
 ;;^UTILITY(U,$J,358.3,16536,2)
 ;;=^5002660
 ;;^UTILITY(U,$J,358.3,16537,0)
 ;;=E11.628^^88^850^27
 ;;^UTILITY(U,$J,358.3,16537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16537,1,3,0)
 ;;=3^Diabetes Type 2 w/ Skin Complications
 ;;^UTILITY(U,$J,358.3,16537,1,4,0)
 ;;=4^E11.628
 ;;^UTILITY(U,$J,358.3,16537,2)
 ;;=^5002658
 ;;^UTILITY(U,$J,358.3,16538,0)
 ;;=E11.630^^88^850^26
 ;;^UTILITY(U,$J,358.3,16538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16538,1,3,0)
 ;;=3^Diabetes Type 2 w/ Periodontal Disease
 ;;^UTILITY(U,$J,358.3,16538,1,4,0)
 ;;=4^E11.630
 ;;^UTILITY(U,$J,358.3,16538,2)
 ;;=^5002659
 ;;^UTILITY(U,$J,358.3,16539,0)
 ;;=E11.8^^88^850^28
 ;;^UTILITY(U,$J,358.3,16539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16539,1,3,0)
 ;;=3^Diabetes Type 2 w/ Unspec Complications
 ;;^UTILITY(U,$J,358.3,16539,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,16539,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,16540,0)
 ;;=E11.9^^88^850^29
 ;;^UTILITY(U,$J,358.3,16540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16540,1,3,0)
 ;;=3^Diabetes Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,16540,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,16540,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,16541,0)
 ;;=E11.36^^88^850^9
 ;;^UTILITY(U,$J,358.3,16541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16541,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Cataract
 ;;^UTILITY(U,$J,358.3,16541,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,16541,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,16542,0)
 ;;=E11.22^^88^850^10
 ;;^UTILITY(U,$J,358.3,16542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16542,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,16542,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,16542,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,16543,0)
 ;;=E11.29^^88^850^12
 ;;^UTILITY(U,$J,358.3,16543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16543,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Kidney Complication
 ;;^UTILITY(U,$J,358.3,16543,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,16543,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,16544,0)
 ;;=E11.21^^88^850^13
 ;;^UTILITY(U,$J,358.3,16544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16544,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,16544,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,16544,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,16545,0)
 ;;=E11.39^^88^850^16
 ;;^UTILITY(U,$J,358.3,16545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16545,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Ophthalmic Complication
 ;;^UTILITY(U,$J,358.3,16545,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,16545,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,16546,0)
 ;;=E11.311^^88^850^20
 ;;^UTILITY(U,$J,358.3,16546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16546,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,16546,1,4,0)
 ;;=4^E11.311
